Please cancel claims 28, and 65-67 without prejudice.

Please amend the claims as follows (all of the claims under consideration, whether or not amended, are presented below for the convenience of the Examiner):

70. The method of claim 73, wherein the step of contacting is performed in vitro.

E2

71. The method of claim 73, wherein the step of contacting is performed in vivo.

72. The method of claim 73, wherein the B7-2 is human B7-2.

Please add the following new claims:

73. A method for blocking binding interactions of B7-2 with CD28 or CTLA4 on an immune cell, comprising contacting the immune cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:2 to thereby block the binding interactions of B7-2 with CD28 or CTLA4 on the immune cell.

E3

74. The method of claim 73, wherein the antibody is a polyclonal antibody.

75. The method of claim 73, wherein the antibody is a monoclonal antibody.

76. The method of claim 73, wherein the antibody is a chimeric antibody.

77. The method of claim 73, wherein the antibody is a humanized antibody

78. The method of claim 73, wherein the antibody is a human antibody.

79. The method of claim 73, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

80. The method of claim 73, wherein the antibody is selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

E3

81. A method for inhibiting proliferation of a T cell comprising contacting a cell bearing B7-2 with an antibody that recognizes the polypeptide shown in SEQ ID NO:2 to thereby inhibit the proliferation of the T cell.

82. The method of claim 81, wherein the step of contacting is performed in vitro.

83. The method of claim 81, wherein the step of contacting is performed in vivo.

84. The method of claim 81, wherein the B7-2 is human B7-2.

85. The method of claim 81, wherein the antibody is a polyclonal antibody.

86. The method of claim 81, wherein the antibody is a monoclonal antibody.

87. The method of claim 81, wherein the antibody is a chimeric antibody.

88. The method of claim 81, wherein the antibody is a humanized antibody

89. The method of claim 81, wherein the antibody is a human antibody.

90. The method of claim 81, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

E3

91. The method of claim 81, wherein the antibody is selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

92. The method of claim 81, further comprising contacting the cell with an additional immunosuppressive agent.

93. A method for inhibiting cytokine production by a T cell comprising contacting a cell bearing B7-2 with an antibody that recognizes the polypeptide shown in SEQ ID NO:2, thereby inhibiting cytokine production by the T cell.

94. The method of claim 93, wherein the step of contacting is performed in vitro.

95. The method of claim 93, wherein the step of contacting is performed in vivo.

96. The method of claim 93, wherein the B7-2 is human B7-2.

97. The method of claim 93, wherein the antibody is a polyclonal antibody.

98. The method of claim 93, wherein the antibody is a monoclonal antibody.

99. The method of claim 93, wherein the antibody is a chimeric antibody.

E-3

100. The method of claim 93, wherein the antibody is a humanized antibody

101. The method of claim 93, wherein the antibody is a human antibody.

102. The method of claim 93, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

103. The method of claim 93, wherein the antibody is selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

104. The method of claim 93, further comprising contacting the cell with an additional immunosuppressive agent.

105. A method for downregulating an immune response comprising administering an antibody that recognizes the polypeptide shown in SEQ ID NO:2 to a subject, such that an immune response is downregulated.

106. The method of claim 105, wherein the antibody is administered prophylactically.

107. The method of claim 105, wherein the antibody is administered therapeutically.

108. The method of claim 105, wherein the subject is a human subject.

E3

109. The method of claim 105, wherein the antibody is a polyclonal antibody.

110. The method of claim 105, wherein the antibody is a monoclonal antibody.

111. The method of claim 105, wherein the antibody is a chimeric antibody.

112. The method of claim 105, wherein the antibody is a humanized antibody

113. The method of claim 105, wherein the antibody is a human antibody.

114. The method of claim 105, wherein the antibody is a $F(ab')_2$ or an Fab' fragment.

115. The method of claim 105, wherein the antibody is selected from the group consisting of: ATCC accession number HB 11688, ATCC accession number HB 11687, and ATCC accession number HB 11686.

116. The method of claim 105, further comprising contacting the cell with an additional immunosuppressive agent.

117. The method of claim 105, wherein the agent is an anti-B7-1 antibody.

118. The method of claim 105, wherein the agent is an immunosuppressive drug.

119. A method for blocking binding interactions of B7-2 with CD28 or CTLA4 on an immune cell, comprising contacting the immune cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:23 to thereby block the binding interactions of B7-2 with the ligand on the immune cell.

120. A method for inhibiting proliferation of a T cell comprising contacting the T cell with an antibody that recognizes the polypeptide shown in SEQ ID NO:23 to thereby inhibit the proliferation of the T cell.